project | all (n = 75) | group 1 (n = 35) | group 2 (n = 20) | group 3 (n = 20) | F/X2 | P | |
Gender (male) (n) | 44 (58.67) | 17 (48.57) | 11 (55.00) | 15 (75.00) | 3.645 | 0.162 | |
Age (years) | 43.00 (31.00, 53.00) | 38.00 (30.00, 46.00) | 58.50 (46.00, 66.75)ac | 34.00 (26.00, 43.75) | 9.195 | <0.001 | |
Main underlying diseases | Hypertension (n) | 9 (12.00) | 1 (2.86) | 7 (35.00)a | 1 (5.00)c | 13.535 | 0.001 |
Diabetes (n) | 4 (5.33) | 2 (5.71) | 2 (10.00) | 0 (0.00) | 1.973 | 0.373 | |
Main comorbidities | Pneumonia (n) | 18 (24.00) | 10 (28.57) | 7 (35.00) | 1 (5.00)bc | 5.610 | 0.060 |
Liver dysfunction (n) | 16 (21.33) | 4 (11.43) | 7 (35.00)a | 5 (25.00) | 4.373 | 0.112 | |
Anemia (n) | 6 (8.00) | 2 (5.71) | 4 (20.00) | 0 (0.00)c | 5.822 | 0.054 | |
Electrolyte disturbance (n) | 11 (14.67) | 2 (5.71) | 9 (45.00)a | 0 (0.00)c | 20.110 | <0.001 | |
Main adverse drug reactions | Gastrointestinal system abnormalities (n) | 23 (30.67) | 13 (37.14) | 4 (20.00) | 6 (30.00) | 1.741 | 0.419 |
Rash (n) | 3 (4.00) | 3 (8.57) | 0 (0.00) | 0 (0.00) | 3.524 | 0.172 | |
Abnormal liver function (n) | 8 (10.67) | 2 (5.71) | 4 (20.00) | 2 (10.00) | 2.702 | 0.259 | |
Conversion (Light to Normal or Normal to Heavy) (n) | 22 (29.33) | 9 (25.71) | 7 (35.00) | 6 (30.00) | 0.528 | 0.768 | |
Discharge status (cured) (n) | 66 (88.00) | 30 (85.71) | 18 (90.00) | 18 (90.00) | 0.320 | 0.852 | |
Symptom onset to treatment time (d) | 2.00 (1.00, 5.00) | 2.00 (1.00, 7.00) | 3.00 (1.00, 5.00) | 1.00 (1.00, 1.75)bc | 6.129 | 0.003 | |
Time for nucleic acid to turn negative (d) | 9.00 (6.00, 16.00) | 7.00 (5.00, 13.00) | 10.00 (5.00, 15.00) | 16.00 (8.25, 25.75)bc | 7.053 | 0.002 | |
Hospitalization time (d) | 16.00 (13.00, 22.00) | 13.00 (12.00, 17.00) | 18.50 (15.25, 21.00) | 21.50 (15.25, 27.75)bc | 5.038 | 0.009 |